Atomwise uses Deep Learning Neural Networks to help discover new medicines. Atomwise achieves the world’s best results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, startups, and research institutions.
Abraham Heifets is cofounder and CEO of Atomwise. He was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched compilers for high-performance data processing at IBM's T.J. Watson Research Center and helped build the AI system of the world-champion robotic soccer team at Cornell University. He was Time's Person of the Year in 2006.